Your browser doesn't support javascript.
loading
Characteristics of state prescription drug monitoring programs: a state-by-state survey.
Manasco, A Travis; Griggs, Christopher; Leeds, Rebecca; Langlois, Breanne K; Breaud, Alan H; Mitchell, Patricia M; Weiner, Scott G.
Afiliación
  • Manasco AT; Department of Emergency Medicine, Boston Medical Center, Boston, MA, USA.
  • Griggs C; Department of Emergency Medicine, Carolinas Medical Center, Charlotte, NC, USA.
  • Leeds R; Tufts University School of Medicine, Boston, MA, USA.
  • Langlois BK; Department of Emergency Medicine, Boston Medical Center, Boston, MA, USA.
  • Breaud AH; Department of Emergency Medicine, Boston Medical Center, Boston, MA, USA.
  • Mitchell PM; Boston University School of Medicine, Boston, MA, USA.
  • Weiner SG; Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Pharmacoepidemiol Drug Saf ; 25(7): 847-51, 2016 07.
Article en En | MEDLINE | ID: mdl-27061342
OBJECTIVES: Prescription drug monitoring programs (PDMPs) are state-based data collection systems recording controlled substance medications. Currently, 49 states have PDMPs. There are discrepancies in reporting patterns, infrastructure, and oversight between programs. We characterized aspects of each state's PDMP. METHODS: A web search of each state's PDMP was conducted, and a list of all PDMP administrators was obtained. From August 1 to November 31, 2014, a link to a web-based survey was sent to each PDMP administrator. Closed-ended questions included type of access, mandatory-use programs, data sharing, proactive contact with patients or health care providers, details of pharmacy reporting, and protocols for identifying "high-risk" patients. Descriptive statistics were used for analysis. RESULTS: We received a 100% response rate (49/49). Ninety-six percent (47/49) have a physician-accessible PDMP. Most, 68% (32/49), do not have an enrollment mandate for physicians. Prior to prescribing controlled medications, 16% (8/49) require prescribers to access their state's PDMP. More than half of states (53%, 26/49) reported patient prescriptions over the past two or more years. Most, 57% (28/59), reported a lag time of 1 week or longer for patients to appear in a PDMP database after prescription filling. A majority of states (65% 32/49) share data with at least one other state. Protocols exist to identify high-risk patients for prescription drug misuse in 55% (27/49) of states. CONCLUSION: Characteristics of PDMPs are heterogeneous throughout the country. Standardizing data capture, availability, and reporting would improve their usefulness for providers. Copyright © 2016 John Wiley & Sons, Ltd.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pautas de la Práctica en Medicina / Medicamentos bajo Prescripción / Sustancias Controladas / Mal Uso de Medicamentos de Venta con Receta Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Pharmacoepidemiol Drug Saf Asunto de la revista: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pautas de la Práctica en Medicina / Medicamentos bajo Prescripción / Sustancias Controladas / Mal Uso de Medicamentos de Venta con Receta Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Pharmacoepidemiol Drug Saf Asunto de la revista: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido